A. DiFrancesco

Phase I Studies of Interleukin (IL)-2 and Rituximab in B-Cell Non-Hodgkin’s Lymphoma

William Larry Gluck, Deborah Hurst, Alan R. Yuen et al. · Clinical Cancer Research · 2004 · 165 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +17

Lorecivivint, a Novel Intraarticular CDC‐like Kinase 2 and Dual‐Specificity Tyrosine Phosphorylation‐Regulated Kinase 1A Inhibitor and Wnt Pathway Modulator for the Treatment of Knee Osteoarthritis: A Phase II Randomized Trial

Timothy E. McAlindon, Allan Gibofsky, Nancy E. Lane et al. · Arthritis & Rheumatology · 2020 · 142 citations · Full text

Medicine, Orthopedic Surgery, Pharmacology +17

A novel Wnt pathway inhibitor, SM04690, for the treatment of moderate to severe osteoarthritis of the knee: results of a 24-week, randomized, controlled, phase 1 study

Timothy E. McAlindon, Roy Fleischmann, Allan Gibofsky et al. · Osteoarthritis and Cartilage · 2017 · 132 citations · Full text

Medicine, Orthopaedic Surgery, Pharmacology +16

A Phase 2b randomized trial of lorecivivint, a novel intra-articular CLK2/DYRK1A inhibitor and Wnt pathway modulator for knee osteoarthritis

T.E. McAlindon, Allan Gibofsky, Nancy E. Lane et al. · Osteoarthritis and Cartilage · 2021 · 107 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Safety and immunogenicity of adjuvanted and unadjuvanted subunit influenza vaccines administered intranasally to healthy adults

Thomas G. Boyce, Henry H. Hsu, Edith C. Sannella et al. · Vaccine · 2000 · 79 citations

Veterinary Medicine, Immunology, Infectious Diseases +14